OncoMatch/Clinical Trials/NCT06281678
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Is NCT06281678 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies IBI363 for melanoma.
Treatment: IBI363 — This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Advanced Solid Malignancies
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: within 2 weeks or 5 plasma half-lives prior to first dose
Any chemotherapy or targeted small molecule therapy (standard or investigational) within 2 weeks or 5 plasma half-lives
Cannot have received: targeted small molecule therapy
Exception: within 2 weeks or 5 plasma half-lives prior to first dose
Any chemotherapy or targeted small molecule therapy (standard or investigational) within 2 weeks or 5 plasma half-lives
Cannot have received: nitrosoureas
Exception: within 6 weeks prior to first dose and during study
Received Nitrosoureas and mitomycin C within 6 weeks prior to first dose of study drug and during study
Cannot have received: mitomycin C (mitomycin C)
Exception: within 6 weeks prior to first dose and during study
Received Nitrosoureas and mitomycin C within 6 weeks prior to first dose of study drug and during study
Cannot have received: anti-cancer monoclonal antibody
Exception: within 4 weeks prior to first dose
Any anti-cancer monoclonal antibody (mAb) within 4 weeks prior to first dose
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco (UCSF) · San Francisco, California
- Ocala Oncology Center · Ocala, Florida
- BRCR Medical Center · Plantation, Florida
- University of Kansas Medical Center (KUMC) · Fairway, Kansas
- Michigan Hematology & Oncology Consultants - MedOnc Dearborn · Dearborn, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06281678 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, targeted small molecule therapy, nitrosoureas disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages